“Global Macular Degeneration (AMD) and Other Retinal Diseases Drugs industry and market set to grow to $23bn by 2024” says Visiongain report

31 July 2019
Pharma

Visiongain has launched a new pharma report Macular Degeneration and Other Retinal Diseases Drugs Market : Wet AMD, Dry AMD, Diabetic Retinopathy, Lucentis, Eylea, Avastin, Visudyne.

The sector has obvious growth potential, since the majority of the AMD and DR patient population currently still lack any treatment options. This means that there are vast patient populations for manufacturers to target with new AMD and DR products, and new candidates in these areas can hope for fast track status from regulatory bodies.

The lead analyst of the report commented "Another question-mark that hangs over the future of the AMD and DR pharmaceuticals sector is the widespread belief that the best cure for these conditions is not biological or small-molecule drug interventions that can stabilise or reverse disease progression, but rather prevention: a therapeutic approach that can stop AMD and DR developing in the first place is widely seen as the major goal by scientists and clinicians working in the field."

Leading companies featured in the report include Acucela, Inc., Allergan Plc, Bayer AG, F. Hoffman-La Roche, Ltd., GlaxoSmithKline Pharmaceuticals, Ltd., Novartis AG, Pfizer, Inc., Valent Pharmaceuticals International, Plc and other companies.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Checkpoint Inhibitors for Treating Cancer Market Report 2021-2031

We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

29 July 2021

Read

Visiongain Publishes Direct-to-Patient Market Report 2021-2031

Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.

21 July 2021

Read

Visiongain Publishes Drug Delivery Technologies Market Report 2021-2031

Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.

20 July 2021

Read

Visiongain Publishes Pharma Contract Sales Market Report 2021-2031

Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.

14 July 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever